A Randomized Phase II Trial Comparing RhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus Carboplatinum/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Bradley Somer, MD
OncoLink Assistant Editor
Ultima Vez Modificado: 23 de mayo del 2000

Translation for this article does not exist